Navigation Links
Lycera Closes $36 Million Series A Financing
Date:4/16/2009

ANN ARBOR, Mich., April 16 /PRNewswire/ -- Lycera Corp. today announced it has closed a $36 million Series A financing.

The company, which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, has received $10 million as a first tranche of the financing and will receive the remainder of the proceeds in two tranches as specific milestones are met. InterWest Partners, ARCH Venture Partners and Clarus Ventures co-led the financing. EDF Ventures, which led a seed financing in November 2006, is also participating.

In conjunction with the closing, Jeffrey Leiden, M.D., Ph.D., a managing director with Clarus; Kristina Burow, a partner with ARCH; and Nina Kjellson, a general partner with InterWest, have joined Lycera's board of directors. These additions have increased board membership to six. Steven Gillis, Ph.D., a managing director with ARCH, and Mary Campbell, a managing director at EDF Ventures, will serve as board observers.

Lycera also announced that it has expanded its development initiatives for small-molecule immunomodulators through the addition of a program targeting the Th17 pathway discovered by Dan Littman, M.D., Ph.D. Dr. Littman, the Helen L. and Martin S. Kimmel professor of molecular immunology and professor of pathology and microbiology at the Skirball Institute of Biomolecular Medicine of New York University School of Medicine, an investigator of the Howard Hughes Medical Institute, and a member of the National Academy of Sciences, will serve as chairman of the company's scientific advisory board.

"This financing round is an important validation of the Lycera technology platforms," said Dr. Gary Glick, Lycera's founder and chief scientific officer. "The company is fortunate to be working with a distinguished, talented and experienced group of investors. Their expertise in the dis
'/>"/>

SOURCE Lycera Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG
2. Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes
3. Cell Biosciences Closes $10 Million Series C Financing
4. Index Ventures Closes Euro 350 Million Early Stage Fund
5. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
6. Opsona Therapeutics Closes EUR18M Funding
7. iCo Therapeutics Closes $1.3 Million Private Placement
8. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
9. Lytix Closes USD 10.4 Million Funding Round
10. Singulex Closes $19 Million Financing Round
11. Karolinska Development Closes Fully Subscribed New Share Issue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
(Date:7/10/2014)... 10, 2014 EvoDerma ’s NOOME Anti-Aging ... rejuvenating device now comes with a second treatment cup to ... , The new cup is thinner on the edges for ... target rough, thin and uneven surfaces on the face, neck ... a stimulating treatment on areas such as the cheeks and ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... a Financial Crisis, Draws Regional Biopharmaceutical Executives, Investment Leaders ... Biotech companies throughout the country are reeling from the ... funds slated to run out of cash before 2010, ... a life sciences symposium presented by Yankee ...
... Spectral Diagnostics Inc. (TSX:SDI), a company developing products ... findings demonstrating the Toraymyxin(TM) cartridge, a blood purification ... added to conventional therapy, significantly improved hemodynamics and ... with severe sepsis and septic shock. The article ...
... can anticipate a future event and prepare for it, ... Science. In a paper that appeared today in ... and research associate Dr. Orna Dahan of the Institute,s ... Gal Romano of Tel Aviv University, examined microorganisms living ...
Cached Biology Technology:Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 5Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial 2Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial 3Israeli scientists show bacteria can plan ahead 2Israeli scientists show bacteria can plan ahead 3
(Date:7/11/2014)... to study the proteins that let nerve cells send ... stumbled upon a biological tactic that may offer a ... a safe and environmentally responsible way. , Their ... one species and harmless for a closely related onesuggests ... without harming beneficial species like bees. A summary of ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP ... Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and ... in United States District Court, Middle District of ... on behalf of a class consisting of all ... Provectus securities between December 17, 2013 and May ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3'Tailored' water -- the latest in lawn care 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... fathers who are active in their children,s upbringing can significantly ... Now, a new study by University of South Florida ... born may play an important role in preventing death during ... is black. The USF team sought to evaluate ...
... RICHMOND, Va. , June 17 Commercializing University Technology ... 29 presented by LeClairRyan and a panel of industry experts from ... , , ... rise again, entrepreneurs, start-ups and emerging businesses should investigate all options to ...
... gestures have intentional meaning and are made with the ... and Richard Byrne from the University of St. Andrews ... communication takes a significant step forward with the authors, ... gestural communication of non-humans, applied here to a group ...
Cached Biology News:Father involvement in pregnancy could reduce infant mortality 2Free Webinar to Focus on Commercializing University Technology 2Free Webinar to Focus on Commercializing University Technology 3Signal like you mean it 2
...
...
... System is an imaging based plate ... and high throughput screening which can ... The Hamamatsu light sources and cameras ... decades-long experience in photon detection technology. ...
... pCITE-2a-c(+) vectors are designed for enhanced translation of ... e.g. rabbit reticulocyte lysate. The maps for pCITE-2b(+) ... the following exceptions: pCITE-2b(+) is a 3793 bp ... I and Xcm I sites. Subtract 7 bp ...
Biology Products: